Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.42 |
| ▸ | WNT3A | P56704 | 5/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829927 | 0.79 | GAA (0.43) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL29000829 | 0.77 | CES2 (0.53) | LMNAGAASMN1; SMN2 | |
| SCHEMBL10137791 | 0.77 | LMNA (0.55) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL3396782 | 0.77 | LMNA (0.55) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL9579838 | 0.77 | LMNA (0.55) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL27558560 | 0.75 | GAA (0.45) | LMNAGAACNR2 | |
| SCHEMBL29256271 | 0.75 | LMNA (0.53) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL4710154 | 0.75 | LMNA (0.53) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL13558725 | 0.74 | RAPGEF3 (0.40) | LMNAGAAKCNK3KCNK9 | |
| SCHEMBL2026595 | 0.74 | LMNA (0.42) | LMNAGAAPTPRCKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040059122-A1 | Cyanothioacetamide derivative and process for producing the same | NIPPON SODA CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1367049-A1 | CYANOTHIOACETAMIDE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NIPPON SODA CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059122-A1 | Cyanothioacetamide derivative and process for producing the same | NAT1, ACAA2, ACAT2 | LMNA 2845/4885GAA 1892/4885CTNNB1 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.